Yesterday in Miami, WPLG Local10 aired a segment spotlighting Mount Sinai MedicalCenter and Dr. AlanNieder’s use of Blue Light Cystoscopy with Cysview (hexaminolevulinate). Take a look at how this exciting information was shared in that local market. http://bit.ly/MtSinaiJan19
Local News Segment Airs on Miami TV
CBS NewsChannel5 Feature: Blue Light Cystoscopy with Cysview
Photocure Inc., is pleased to announce NewsChannel5, the CBS affiliate in Nashville, TN, USA has featured the story of Bladder Cancer Survivor Mary Beth Ballard Murray, who is coming up on her five years survivorship. She was treated at Vanderbilt Hospital in Nashville, TN, by Dr. Sam Chang who is the Patricia & Rodes Hart Endowed Chair of Urologic Surgery and Professor, Department of Urology, where she received a Blue Light Cystoscopy with Cysview for the management of her Bladder Cancer. Watch her story on the station website.
Enhanced cystoscopy (BLC™ with Cysview®) has an important role in the management of bladder cancer patients
New data on Urine Cytology in the management of bladder cancer patients is now published in the prestigious peer reviewed BJUI journal (British Journal of Urology International). The analysis shows that relying on Cytology alone, especially for high risk patients, would miss early detection and BCG unresponsiveness in NMIBC (non-muscle invasive bladder cancer).
The results are from further analysis of three published phase III studies. The analysis is of 1487 urine samples from 1375 patients, overall 615 tumors were detected correlating to 41% of the cytological specimens. Click here http://bit.ly/BLC-Urine-Cytology for the full the article.
“Based on analysis of contemporary data, the sensitivity of cytology for detecting High Grade and CIS (carcinoma in situ) tumors remains low. The data supports the use of enhanced cystoscopy techniques, such as BLC with Cysview, which I now use for both the surveillance and TURBT in many of my patients,” says Dr. Yair Lotan, Urology Professor Helen J. and Robert S. Strauss Professorship in Urology at University of Texas, South Western (UTSW) and lead author on the publication.
The important role of Hexvix®/ Cysview® in the detection and management of bladder cancer highlighted at the BLADDR 2018 congress.
Dr. Ashish Kamat, from the University of Texas MD Andersson Cancer Center, addressed the key role of Blue Light Cystoscopy (BLC™) with Hexvix/Cysview in his opening lecture “Overcoming barriers to progress in NMIBC – Where are we in 2018 and where will we be in 5 years?” and challenged the current gold standard when it comes to tumor detection to bring the management of bladder cancer from the past to future standards. Read more here: https://bit.ly/2xGkbKc
Dr. Siamak Daneshmand, from the University of Southern California, gave a presentation on “Contemporary advances in the endoscopic evaluation and diagnosis of bladder cancer”, demonstrating how BLC with Hexvix/Cysview change the management of bladder cancer patients, including in the follow up with flexible cystoscopy. Dr. Daneshmand reviewed the large body of evidence showing increased detection rates and reduced rates of recurrence and progression in Non-Muscle Invasive Bladder Cancer. He also summarized the data from the recently published Phase III U.S. trial on in-office use of BLC with Cysview for surveillance cystoscopy which demonstrated similar increased detection rates for both papillary tumors and carcinoma in-situ (CIS).
MD Marie Schmidt Erikson, Herlev and Gentofte Hospital, Copenhagen presented a poster on future perspectives for outpatient management including BLC guided diode laser treatment demonstrating the opportunities for completion of treatment in a minor procedure in the awake patient.